Targeting Liver X Receptors in Cancer Drug Discovery
Open Access
Abstract
Liver X receptors (LXRs) are members of the nuclear receptor superfamily of ligand-dependent transcription factors. LXRα is predominantly expressed in metabolic tissues, whereas LXRβ is ubiquitously expressed. Upon ligand binding, they regulate the expression of target genes involved in lipid metabolism, cholesterol homeostasis, and immune responses, including those which function in pathways that are commonly reprogrammed during carcinogenesis. Known LXR ligands include oxysterols and natural and synthetic agonists which upregulate LXR transcriptional activity and target gene expression. Synthetic inverse agonists have also been identified that inhibit LXR activity. While both types of ligands have been shown to inhibit cancer cells and tumor growth either directly or indirectly by modulating the activities of stromal cells within the tumor microenvironment, they appear to target different aspects of cancer metabolism and other cancer hallmarks, including immune evasion. This review summarizes the characterization of LXRs and their ligands and their mechanisms of action in cancer models and discusses the future directions for translating these discoveries into novel cancer therapeutics.Keywords
Funding Information
- Golfers Against Cancer
- William & Ella Owens Medical Research Foundation
This publication has 142 references indexed in Scilit:
- Taurine Inhibits Ferroptosis Mediated by the Crosstalk between Tumor Cells and Tumor‐Associated Macrophages in Prostate CancerAdvanced Science, 2023
- Liver X receptors induce antiproliferative effects in basal‐like breast cancerMolecular Oncology, 2023
- Development of Light‐Activated LXR AgonistsChemMedChem, 2023
- ATF4/TXNIP/REDD1/mTOR signaling mediates the antitumor activities of liver X receptor in pancreatic cancersCancer Innovation, 2022
- Activation of LXRβ inhibits proliferation, promotes apoptosis, and increases chemosensitivity of gastric cancer cells by upregulating the expression of ATF4Journal of Cellular Biochemistry, 2019
- The nuclear receptor superfamily: A structural perspectiveProtein Science, 2018
- Treatment of colon cancer with liver X receptor agonists induces immunogenic cell deathMolecular Carcinogenesis, 2018
- Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatmentFEBS Open Bio, 2016
- The oxysterol receptors lxrα and lxrβ suppress proliferation in the colonMolecular Carcinogenesis, 2012
- Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitisJournal of Neuroscience Research, 2006